GlassScriptPhysician profile
Dat Huu Tran
NPI 1588018097
$1,187.30
in general payments reported to CMS, 2019-2025
24 companies · $961 in 2025
The $961 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.36 · 2021: $95.00 · 2022: $120 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $960.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $195.68 | 2025 | Monjuvi, Monjuvi, Jakafi |
| E.R. Squibb & Sons, L.L.C. | $134.99 | 2025 | Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $105.42 | 2022 | |
| Amgen INC. | $95.00 | 2021 | |
| Janssen Biotech, INC. | $70.18 | 2025 | Carvykti, Rybrevant, Erleada |
| Astellas Pharma US INC | $62.07 | 2025 | Vyloy |
| Novartis Pharmaceuticals Corporation | $57.14 | 2025 | |
| Merck Sharp & Dohme LLC | $50.45 | 2025 | Keytruda, Lynparza |
| Caris Mpi, INC. | $41.66 | 2025 | Mi Cancer Seek |
| Pfizer INC. | $39.12 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $36.74 | 2025 | Sancuso |
| Servier Pharmaceuticals LLC | $36.62 | 2025 | |
| Pharmaessentia USA Corporation | $34.05 | 2025 | Besremi |
| Eisai INC. | $27.68 | 2025 | |
| Tolmar, INC. | $25.22 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $23.99 | 2025 | |
| Gilead Sciences, INC. | $23.28 | 2025 | Trodelvy |
| Lilly USA, LLC | $21.93 | 2025 | Verzenio, Jaypirca |
| Acrotech Biopharma INC. | $21.76 | 2025 | Beleodaq |
| Progenics Pharmaceuticals, INC. | $21.39 | 2025 | |
| Stemline Therapeutics INC. | $20.52 | 2025 | Orserdu |
| Corcept Therapeutics | $16.09 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $14.96 | 2022 | |
| Celgene Corporation | $11.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dat Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.